These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 14764172)

  • 1. Effects of intravenous nifekalant, a class III antiarrhythmic drug, on atrial vulnerability parameters in patients with paroxysmal atrial fibrillation.
    Minami T; Isomoto S; Nakao K; Komiya N; Fukae S; Centurion OA; Yano K
    Pacing Clin Electrophysiol; 2004 Feb; 27(2):212-7. PubMed ID: 14764172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Nifekalant in Patients With Wolff-Parkinson-White Syndrome and Atrial Fibrillation: Electrophysiological and Clinical Findings.
    Hu J; Yu J; Chen Q; Hu J; Huang Q; Xia Z; Xia Z; Ju Z; Yuan P; Fan S; Xiong Q; Zhu B; Huang L; You C; Bao H; Wu Y; Cheng X; Li J; Marian AJ; Hong K
    J Am Heart Assoc; 2019 Jul; 8(13):e012511. PubMed ID: 31234695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiological effects of MS-551 in humans: a class III antiarrhythmic agent.
    Isomoto S; Konoe A; Centurion OA; Hayano M; Kaibara M; Hirata T; Yano K
    Pacing Clin Electrophysiol; 1995 Nov; 18(11):2022-7. PubMed ID: 8552516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of IKr blocker nifekalant on atrial action potential duration after successful internal cardioversion of chronic atrial fibrillation.
    Kofune T; Watanabe I; Okubo K; Okumura Y; Masaki R; Shindo A; Saito S
    Pacing Clin Electrophysiol; 2005 May; 28(5):391-6. PubMed ID: 15869670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical assessment of antiarrhythmic agents for paroxysmal atrial fibrillation guided by modification of electrophysiologic arrhythmogenicity.
    Sasano T; Okishige K; Azegami K; Isobe M
    J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1250-7. PubMed ID: 15574173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic effect of nifekalant on atrial tachyarrhythmia in four patients with severe heart failure.
    Shiga T; Matsuda N; Fuda Y; Haruta S; Hagiwara N; Kasanuki H
    J Cardiol; 2002 Mar; 39(3):159-64. PubMed ID: 11912950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate-dependent electrophysiologic effects of the class III antiarrhythmic drugs nifekalant, amiodarone, and ibutilide on the atrium in patients with persistent atrial fibrillation.
    Sonoda K; Watanabe I; Ohkubo K; Okumura Y; Kofune M; Sasaki N; Kogawa R; Mano H; Nakai T; Hirayama A
    Int Heart J; 2013; 54(5):279-84. PubMed ID: 24097216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of intravenous nifekalant cardioversion as an independent predictor for persistent atrial fibrillation recurrence after catheter ablation.
    Ma Y; Guo L; Pang H; Yan Q; Li J; Hu M; Yi F
    J Interv Card Electrophysiol; 2024 Aug; 67(5):1161-1171. PubMed ID: 38051431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical study of the acute effects of intravenous nifekalant on the defibrillation threshold in patients with persistent and paroxysmal atrial fibrillation.
    Okishige K; Uehara H; Miyagi N; Nakamura K; Azegami K; Wakimoto H; Ohba K; Hirao K; Shimabukuro M; Isobe M
    Circ J; 2008 Jan; 72(1):76-80. PubMed ID: 18159104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.
    Wang J; Feng J; Nattel S
    Circulation; 1994 Oct; 90(4):2032-40. PubMed ID: 7923691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiologic effects of a new class III antiarrhythmic agent, E-4031, on atrial flutter, atrial refractoriness, and conduction delay in a canine sterile pericarditis model.
    Shimizu A; Kaibara M; Centurion OA; Kapuku G; Hirata T; Fukatani M; Yano K; Hashiba K
    J Cardiovasc Pharmacol; 1993 Apr; 21(4):656-62. PubMed ID: 7681913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of nifekalant on acute electrical remodelling in rapid atrial pacing canine model.
    Tang M; Zhang S; Sun Q; Hua W; Huang CX
    Chin Med J (Engl); 2006 Dec; 119(24):2056-61. PubMed ID: 17199956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiologic mechanism of typical atrial flutter termination by nifekalant: effect of a pure IKr -selective blocking agent.
    Yamabe H; Tanaka Y; Morihisa K; Uemura T; Koyama J; Kanazawa H; Hoshiyama T; Ogawa H
    Pacing Clin Electrophysiol; 2013 Sep; 36(9):1123-31. PubMed ID: 23607491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation.
    Kirchhof P; Engelen M; Franz MR; Ribbing M; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
    Basic Res Cardiol; 2005 Mar; 100(2):112-21. PubMed ID: 15696400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nifekalant for acute conversion of atrial flutter: the possible termination mechanism of typical atrial flutter.
    Morita N; Tanaka K; Yodogawa K; Hayashi M; Akutsu K; Yamamoto T; Satoh N; Kobayashi Y; Katoh T; Takano T
    Pacing Clin Electrophysiol; 2007 Oct; 30(10):1242-53. PubMed ID: 17897127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing electrical cardioversion and preventing immediate reinitiation of hemodynamically deleterious atrial fibrillation with class III drug pretreatment.
    Hayashi M; Tanaka K; Kato T; Morita N; Sato N; Yasutake M; Kobayashi Y; Takano T
    J Cardiovasc Electrophysiol; 2005 Jul; 16(7):740-7. PubMed ID: 16050832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
    Frommeyer G; Milberg P; Uphaus T; Kaiser D; Kaese S; Breithardt G; Eckardt L
    Cardiovasc Ther; 2013 Dec; 31(6):e63-71. PubMed ID: 23647657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans.
    Dorian P; Pinter A; Mangat I; Korley V; Cvitkovic SS; Beatch GN
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):35-40. PubMed ID: 17666913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of ablation of complex fractionated atrial electrograms using nifekalant in persistent atrial fibrillation.
    Kumagai K; Toyama H
    J Cardiol; 2013 Jan; 61(1):44-8. PubMed ID: 23088936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced dispersion of atrial refractoriness as an electrophysiological substrate for vulnerability to atrial fibrillation in patients with paroxysmal atrial fibrillation.
    Oliveira MM; da Silva N; Timóteo AT; Feliciano J; de Sousa L; Santos S; Marques F; Ferreira R
    Rev Port Cardiol; 2007; 26(7-8):691-702. PubMed ID: 17939579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.